ClinicalTrials.gg
Not yet recruitingNCT07722962Updated Jul 23, 2026

Additional Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury

A Phase 3 interventional study of KP-100IT in Acute Spinal Cord Injury (SCI), sponsored by Kringle Pharma, Inc.. Not yet recruiting at 3 sites in Japan. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by Kringle Pharma, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 89 Years
Sex
All
01

Study summary

This is a Phase 3, multicenter, open-label, single-arm additional study to evaluate the efficacy of intrathecal KP-100IT in patients with acute spinal cord injury. Eligible patients will receive KP-100 0.6 mg/body by intrathecal administration once per week for a total of 5 doses and will be followed for approximately 24 weeks after the first dose.

02

Conditions studied

  • Acute Spinal Cord Injury (SCI)

Keywords

  • KP-100IT
  • Hepatocyte growth factor
  • Intrathecal administration
03

In context

Lead sponsor

Kringle Pharma, Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients whose AIS grade is A at 72 hours (± 6 hours) after injury
  • age: 18 years to 89 years
  • MRI imaging and other tests confirm the continuity of the spinal cord

Exclusion criteria

Exclusion Criteria:

  • The injury site is C1-C2 or C2-C3
  • The patient with a spinal crd compression rate of 70% or higher.
  • The patient in whom a spinal cord rupture is strongle suspected.
  • The patient cannot start rehabilitation necessary for recovery of function at an early stage.
  • External trauma or concurrent organ injury.
  • High dose therapy administered for the treatment of spinal cord injury
  • History or concurrent presence of malignant tumor.
  • It is inappropriate for the subject to be included in the study, in the opinion of the investigator.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    KP-100IT

    Drug: KP-100IT

Interventions

  • The contents of each vial were dissolved in the distilled water for injection, and the study drug (0.6 mg as KP-100) was administered intrathecally once per week a total of 5 times.

06

What researchers measure

Primary outcomes

  1. Percentage of subjects with an improvement of at least two AIS (American Spinal Injury Association) grade, A to C/D, at 24 weeks after administration, 24 weeks

    Time frame: 24 weeks after investigational product administration

Secondary outcomes

  1. Time course of ASIA motor score (total/ upper extremity / lower upper extremity)

    Time frame: From baseline through 24 weeks

  2. Time course of ASIA sensory score

    Time frame: From baseline through 24 weeks

  3. Time course of AIS classification

    Time frame: From baseline through 24 weeks

  4. Time course of modified Frankel classification

    Time frame: From baseline through 24 weeks

  5. Time course of neurological level of injury

    Time frame: From baseline through 24 weeks

  6. Percentage of subjects improving by at least 5 and 10 points on the ASIA motor score at 12 weeks and 24 weeks after administration relative to before study drug administration

    Time frame: 12 weeks and 24 weeks after investigational product administration

  7. Time courses of plasma concentration and cerebrospinal fluid concentration of KP-100 after intrathecal administration

    Time frame: From dosing through 24weeks

  8. Evaluation of adverse events

    Time frame: From the first drug administration through the end of the observation period (24 weeks)

07

Study locations

3 sites
  • Japan Organization for Occupational Health and Safety Comprehensive Spinal Cord Injuries Center
    Iizuka, Fukuoka 820-8508, Japan
    • · Contact+81-948-24-7500
  • Japan Organization for Occupational Health and Safety Hokkaido Spinal Cord Injury Center
    Bibai, Hokkaido 072-0015, Japan
  • National Hospital Organization Murayama Medical Center
    Musashimurayama, Tokyo 208-0011, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for Dec 2028, 29 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2026
First posted
Jul 23, 2026
StartEst.
Jul 31, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07722962
Lead sponsor
Kringle Pharma, Inc.
Responsible party
Sponsor
First posted
Jul 23, 2026
Start date
Jul 31, 2026 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jul 23, 2026

Study contacts

Daichika Hayata
Contact
hayata@kringle-pharma.com
'+81-6-7653-6728
Yurika Abe
Contact
y.abe@kringle-pharma.com
+81-6-7653-6728

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KP-100IT

Start the discussion